Viral Vector and Plasmid DNA Manufacturing Market Set to Expand at 14.2% CAGR | Fueled by Gene Therapy Advancements and Biopharmaceutical Innovation | DataM Intelligence

The viral vector and plasmid DNA manufacturing market size was valued at USD 2.85 billion in 2021 and is growing at a CAGR of 14.2% during the forecast period 2024-2031. This robust growth is propelled by the exponential expansion of gene and cell therapies, increasing prevalence of genetic disorders, rising investments in biopharmaceutical R&D, and advancements in viral vector production technologies that enhance manufacturing efficiency and scalability.

Get a Free Sample PDF Of This Report (Get Higher Priority for Corporate Email ID): https://www.datamintelligence.com/download-sample/viral-vector-and-plasmid-dna-manufacturing-market?jd

Recent Developments (November 2025)

✅ FDA Gene Therapy Acceleration Program - US Food and Drug Administration launched a $250 million initiative to streamline viral vector manufacturing processes, reducing approval times for gene therapies by 30%.

✅ European Gene Therapy Manufacturing Alliance - EU allocated €500 million for establishing Good Manufacturing Practice (GMP) compliant viral vector production facilities across member states to address supply chain challenges.

✅ CRISPR Therapeutics Expansion - Leading gene editing company invested $300 million in scaling up plasmid DNA and viral vector manufacturing capacity to support late-stage clinical trials and commercial readiness.

✅ AAV Vector Production Breakthrough - Novel manufacturing platform increased adeno-associated virus (AAV) vector yields by 400%, significantly reducing production costs for gene therapies.

✅ Global Vaccine Initiative - WHO partnered with major manufacturers to establish regional viral vector production hubs for rapid response to emerging infectious diseases.

Market Trends & Drivers

The Viral Vector and Plasmid DNA Manufacturing Market is experiencing rapid growth driven by the gene therapy revolution, increasing regulatory approvals for advanced therapy medicinal products (ATMPs), and technological innovations in manufacturing processes. Key trends include the adoption of scalable suspension culture systems, implementation of automation and process analytical technologies (PAT), and development of novel viral vector platforms. The growing pipeline of gene therapy candidates, expanding applications in oncology and rare diseases, and increasing outsourcing to CDMOs are significantly accelerating market expansion.

Speak to Our Analyst and Get Customization in the Report: https://www.datamintelligence.com/customize/viral-vector-and-plasmid-dna-manufacturing-market?jd

Competitive Landscape

The market features intense competition between established biopharmaceutical companies, specialized CDMOs, and emerging technology providers.

1. Lonza Group AG launched its GS Xceed® Gene Expression System for enhanced viral vector production, securing $450 million in long-term contracts with gene therapy developers and expanding its Houston facility capacity by 60%.

2. Thermo Fisher Scientific introduced the GibcoTM AAV-MAX Production System, achieving 3-fold higher yields and capturing 35% market share in AAV manufacturing services for ocular and neurological disorders.

3. Catalent, Inc. expanded its viral vector development services with new GMP facilities in Europe and North America, reporting 45% revenue growth in gene therapy manufacturing and securing partnerships with 15 biotech companies.

4. Charles River Laboratories developed the HEK 293 suspension cell platform for scalable lentiviral vector production, reducing manufacturing costs by 40% and serving 200+ clients in CAR-T therapy development.

5. FUJIFILM Diosynth Biotechnologies invested $400 million in new plasmid DNA and viral vector facilities, implementing continuous manufacturing processes that cut production time by 50%.

Buy Now and Enjoy a 30% Year-End Discount: https://www.datamintelligence.com/buy-now-page?report=viral-vector-and-plasmid-dna-manufacturing-market?jd

Segmentation Analysis

By Product Type
• Viral Vector dominates the market, with adeno-associated viruses (AAV) and lentiviruses leading due to their extensive use in gene therapies and cell therapies
• Plasmid DNA shows strong growth as critical starting material for both viral vector production and non-viral gene therapies
• Non-Viral Vector represents the fastest-growing segment, driven by advancements in lipid nanoparticles and electroporation technologies

By Application
• Cancer applications lead the market, particularly driven by CAR-T therapies and oncolytic viruses requiring viral vector manufacturing
• Genetic Disorders represent the fastest-growing segment, with increasing approvals for rare disease treatments and growing pipeline of gene therapies
• Infectious Diseases maintain significant share, supported by viral vector-based vaccine platforms and ongoing pandemic preparedness initiatives

Key Growth Drivers:

1. Gene Therapy Expansion: Rapidly growing pipeline of gene therapy candidates approaching commercialization
2. Rare Disease Focus: Increasing development of treatments for genetic disorders with high unmet medical need
3. Manufacturing Technology Advancements: Innovations in scalable production systems and process optimization
4. Regulatory Support: Streamlined pathways for advanced therapy approvals and orphan drug designations
5. Investment Influx: Significant venture capital and pharmaceutical investments in gene therapy companies
6. CDMO Capacity Growth: Expansion of contract development and manufacturing organizations to address industry capacity constraints

Request for 2 Days FREE Trial Access: https://www.datamintelligence.com/reports-subscription?jd

Regional Analysis:

North America dominates the viral vector and plasmid DNA manufacturing market, supported by advanced healthcare infrastructure, strong regulatory framework, and concentration of gene therapy companies. Europe shows robust growth driven by harmonized regulatory pathways and increasing government support for advanced therapies. The Asia-Pacific region exhibits the fastest growth rate, fueled by expanding biopharmaceutical capabilities, increasing clinical trial activities, and growing investments in gene therapy research and manufacturing infrastructure.

Related Reports:
1. Cell and Gene Therapy Market - https://www.datamintelligence.com/research-report/cell-and-gene-therapy-market?jd
2. DNA Sequencing Market - https://www.datamintelligence.com/research-report/dna-sequencing-market?jd
3. Refurbished DNA Sequencing Platforms Market - https://www.datamintelligence.com/research-report/refurbished-dna-sequencing-platforms-market?jd

Contact Us:
Sai Kiran
DataM Intelligence 4market Research LLP
Phone: +1 877-441-4866
Email: Sai.k@datamintelligence.com

About DataM Intelligence
DataM Intelligence is a renowned provider of market research, delivering deep insights through pricing analysis, market share breakdowns, and competitive intelligence. The company specialises in strategic reports that guide businesses in high-growth sectors such as nutraceuticals and AI-driven health innovations.
To find out more, visit https://www.datamintelligence.com/ or follow us on Twitter, LinkedIn and Facebook.

This release was published on openPR.